Author: Cristiana Vilela1, Bruna Araújo2,3,4, Carla Soares-Guedes1,4, Rita Caridade-Silva4, Joana Martins-Macedo2,3,4, Catarina Teixeira4, Eduardo D Gomes1, Cristina Prudêncio1, Mónica Vieira1, Fábio G Teixeira2,3,4
Affiliation: <sup>1</sup> Center for Translational Health and Medical Biotechnology Research (TBIO)/Health Research Network (RISE-Health), ESS, Polytechnic of Porto, R. Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal.
<sup>2</sup> Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
<sup>3</sup> ICVS/3B's Associate Lab, PT Government Associated Lab, 4710-057/4805-017 Braga/Guimarães, Portugal.
<sup>4</sup> i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal.
Conference/Journal: Cells
Date published: 2024 Apr 30
Other:
Volume ID: 13 , Issue ID: 9 , Pages: 770 , Special Notes: doi: 10.3390/cells13090770. , Word Count: 187
Parkinson's disease (PD) is recognized as the second most prevalent primary chronic neurodegenerative disorder of the central nervous system. Clinically, PD is characterized as a movement disorder, exhibiting an incidence and mortality rate that is increasing faster than any other neurological condition. In recent years, there has been a growing interest concerning the role of the gut microbiota in the etiology and pathophysiology of PD. The establishment of a brain-gut microbiota axis is now real, with evidence denoting a bidirectional communication between the brain and the gut microbiota through metabolic, immune, neuronal, and endocrine mechanisms and pathways. Among these, the vagus nerve represents the most direct form of communication between the brain and the gut. Given the potential interactions between bacteria and drugs, it has been observed that the therapies for PD can have an impact on the composition of the microbiota. Therefore, in the scope of the present review, we will discuss the current understanding of gut microbiota on PD and whether this may be a new paradigm for treating this devastating disease.
Keywords: Parkinson’s disease; gut–brain axis; microbiome.
PMID: 38727306 PMCID: PMC11083070 DOI: 10.3390/cells13090770